Back to today’s briefing

Story perspectives

Study Reveals Higher Risks in Indian Generic Drugs

4/20/2025

23 3

Summary

Story summary

A revealing study from Ohio State University uncovers a troubling truth: generic drugs from India, which dominate 93% of the market in emerging nations, face a staggering 54% higher rate of severe side effects than their U.S. equivalents. Regulatory gaps and lax inspections raise concerns about quality, even as India's generic drug market is set to soar to $35.62 billion by 2030.

1 of 1

Story summary

A revealing study from Ohio State University uncovers a troubling truth: generic drugs from India, which dominate 93% of the market in emerging nations, face a staggering 54% higher rate of severe side effects than their U.S. equivalents. Regulatory gaps and lax inspections raise concerns about quality, even as India's generic drug market is set to soar to $35.62 billion by 2030.